Pharsight

Bevespi Aerosphere patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324266 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

US10716753 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(5 years from now)

US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

US8703806 ASTRAZENECA Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(5 years from now)

US8808713 ASTRAZENECA Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(5 years from now)

US9463161 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(5 years from now)

US8815258 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(6 years from now)

Bevespi Aerosphere is owned by Astrazeneca.

Bevespi Aerosphere contains Formoterol Fumarate; Glycopyrrolate.

Bevespi Aerosphere has a total of 7 drug patents out of which 0 drug patents have expired.

Bevespi Aerosphere was authorised for market use on 25 April, 2016.

Bevespi Aerosphere is available in aerosol, metered;inhalation dosage forms.

Bevespi Aerosphere can be used as use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd).

The generics of Bevespi Aerosphere are possible to be released after 17 March, 2031.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 25, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

BEVESPI AEROSPHERE family patents

Family Patents